Tag: Aeson

CARMAT: The First U.S. Clinical Experience with Aeson® TAH Published in the Annals of Thoracic Surgery Short Reports

The publication highlights the effectiveness of the device based on the combination of hemocompatibility and autoregulation PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a […]

CARMAT Announces the First Implantation of Aeson® Within the Framework of The EFICAS Clinical Study in France

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the first implantation of its Aeson® […]

CARMAT Announces the Resumption of Commercial Implants of its Aeson® Artificial Heart Is Now Effective

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants […]

CARMAT Announces That It Has Received the Necessary Regulatory Approvals to Resume Aeson® Commercial Implants

DEKRA has provided notified body approval of all changes implemented by CARMAT PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, designed to provide a therapeutic alternative for people suffering […]

CARMAT Announces Three Publications About Aeson® in Peer-Reviewed Scientific Journals

Clinical results confirm hemocompatibility and show absence of inflammation after Aeson® implant, with significant potential benefits for patients PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an […]

CARMAT Receives Final Approval From the Patient Protection Committee for the Use of the Commercial Version of the Aeson® Heart in the EFICAS Study in France

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces […]

CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its […]